First-Trimester Down Syndrome Screening: NIPT, Combined Test, and Diagnostic Options

Prenatal screening for trisomy 21 (Down syndrome) before 14 weeks includes non-invasive and invasive options.

Screening Tests (Risk Assessment, Not Diagnostic)

1. Combined First-Trimester Screening (11–14 weeks)

  • Maternal serum: PAPP-A (↓ in trisomy 21), free β-hCG (↑).
  • Nuchal translucency (NT) ultrasound: Increased NT (>3.5 mm or >95th percentile) correlates with aneuploidy and structural defects.
  • Detection rate: ~85–90% for 5% false-positive rate.

2. Cell-Free DNA (cfDNA) / NIPT (from 10 weeks)

  • Analyzes placental DNA in maternal blood. Detects trisomies 21, 18, 13, sex chromosome aneuploidies.
  • Detection rate for trisomy 21: >99%; false-positive rate <0.1%.
  • Not diagnostic—positive results require confirmatory invasive testing.

Diagnostic Tests (Definitive)

  • Chorionic villus sampling (CVS): 10–13 weeks. Transcervical/transabdominal placental biopsy. Miscarriage risk ~0.2–0.5%.
  • Amniocentesis: ≥15 weeks. Amniotic fluid karyotype/CMA. Miscarriage risk ~0.1–0.3%.

Counseling Points

Screening is optional. Positive screen ≠ diagnosis. NIPT has higher sensitivity/specificity but does not detect all chromosomal abnormalities (e.g., balanced translocations, some mosaicism). Diagnostic testing provides certainty but carries procedure risk. Shared decision-making with genetic counseling is standard.

Baby Health - Related Articles